Cingulate therapeutics ipo
WebOct 13, 2024 · Cingulate Therapeutics' IPO date and price. Cingulate is expected to start trading on Oct. 15. The company now plans to raise $40 million by offering 4.4 million … WebSep 30, 2024 · Summary. Cingulate has filed proposed terms for a $50 million IPO. The firm is seeking to develop improved drug delivery technologies and pair them with existing approved drugs for ADHD.
Cingulate therapeutics ipo
Did you know?
WebSee the newest and upcoming IPOs (Initial Public Offerings) announcements and details. Quarterly Earnings Calendar Learn when companies will announce their quarterly … WebApr 10, 2024 · Analyst Forecast. According to 10 analysts, the average rating for CING stock is "Buy." The 12-month stock price forecast is $5.99, which is an increase of 508.12% …
WebSep 16, 2024 · Cingulate Therapeutics IPO - Photo: Shutterstock. Cingulate Therapeutics threw its hat into the ring of biopharmaceutical companies that have … WebCingulate Therapeutics, LLC (CTx) is a privately held, clinical-stage biopharmaceutical company focused on the development of innovative new products utilizing the Company’s disruptive, proprietary Precision Timed Release™ (PTR™) drug delivery platform technology incorporating a proprietary Erosion Barrier Layer (EBL) enabling the creation of true once …
WebDec 8, 2024 · Cingulate Inc. (NASDAQ: CIN), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline ... WebOct 26, 2024 · KANSAS CITY, Kan., Oct. 26, 2024 /PRNewswire/ -- Cingulate Therapeutics, a privately-held, clinical-stage, biopharmaceutical company focused on the development of innovative new products for...
WebCING Complete Cingulate Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
WebDec 9, 2024 · That price was the low end of an already revised range of $6 to $8. Cingulate had originally planned to offer 4.5 million shares at a $10 to $12 range, then lowered the … tsp e learningWebAbout Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery … tsp election limitWebCingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation … tspe houstonWebJul 13, 2024 · Cingulate's stock was trading at $1.00 at the beginning of the year. Since then, CING stock has decreased by 3.8% and is now trading at $0.9619. View the best … t spelthof binkomWebDec 8, 2024 · Cingulate Inc. (NASDAQ: CIN), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform … tspe mid citiesWebOct 8, 2024 · Cognition Therapeutics priced its IPO at the mid-point. Cognition Therapeutics raised $45.2 million by offering 3.8 million shares in the IPO at $12 each. Previously, the company planned to offer ... tsp electronics technologyWebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being … tspe motor